Search Cancer Clinical Trials
Search our clinical trials database by disease type, trial number, location or phase. Must press "Go" to activate search.
Randomized phase II trial, comparing Pemetrexed plus Erlotinib to Pemetrexed alone in EGFR TKI - responsive Non small cell lung cancer
- To evaluate whether maintenance erlotinib added to pemetrexed chemotherapy in patients with erlotinib-responsive advanced non-small cell lung cancer leads to an improved progression-free survival as compared to pemetrexed alone
- To evaluate the effect of maintenance erlotinib on the response rate to pemetrexed therapy in patients with erlotinib-responsive advanced non-small cell lung cancer as compared to pemetrexed alone
- To evaluate whether maintenance erlotinib added to pemetrexed chemotherapy in patients with erlotinib-responsive advanced non-small cell lung cancer leads to an improved overall survival as compared to pemetrexed alone
- To evaluate the effect of maintenance erlotinib on the disease stabilization (CR + PR + SD) rate to pemetrexed therapy in patients with erlotinib-responsive advanced nonsmall cell lung cancer as compared to pemetrexed alone
- To evaluate the utility of early PET scanning (baseline versus 1 cycle of protocol therapy) on overall disease assessment and prediction of treatment responsiveness
- Pathologic diagnosis of stage IIIB (with pleural effusion) or IV non-small cell lung cancer.
- Progression following at least twelve weeks of treatment with single-agent erlotinib during which time the patients experienced a clinical benefit as assessed by his/her treating physician and corroborated by radiographic assessment (at least one CT scan following at least 4 weeks of erlotinib monotherapy demonstrating stable disease or response on erlotinib monotherapy)
- At least one measurable lesion as defined by modified RECIST criteria
- ECOG performance status of 0-2
- Age ≥18 years
- Life expectancy of at least 12 weeks
- Screening laboratory values within following parameters:
- ANC ≥ 1.5x10(9)/L
- Platelet count ≥ 100x 10(9)
- Hemoglobin ≥ 8.0 g/dl
- Serum creatinine ≤1.5 upper limit of normal OR calculated creatinine clearance ≥45 mL/min
- Total bilirubin ≤1.5 x ULN
- AST and ALT ≤2.5 x ULN
- Available baseline diagnostic tumor specimen for correlative studies (any diagnostic material will be acceptable-paraffin block, cell block, fine needle aspirate etc.)
- Patients must provide verbal and written informed consent to participate in the study.
- Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
- Patient must be able to take folic acid, vitamin B12 as well as dexamethasone therapy as per protocol guidelines.
- Patient must be able to interrupt NSAIDS 2 days before (5 days for long-acting NSAIDs), the day of, and 2 days following administration of pemetrexed (this exclusion criteria applies only to patients who have not received pemetrexed chemotherapy prior).
- Active central nervous system disease (CNS) metastases, as indicated by clinical symptoms, cerebral edema or progressive growth (subjects with a clinical history of CNS metastases or cord compression are allowable if they have been definitively treated and are clinically stable for at least 4 weeks before first dose of study treatment for prior whole brain radiation and 2 weeks for prior gamma knife therapy).
- More than 1 prior cytotoxic chemotherapy regimen for relapsed or metastatic disease (not including erlotinib).
- Any prior EGFR inhibitor therapy except for erlotinib
- Major surgery, chemotherapy, or investigational agents within 3 weeks of treatment day 1 (except for erlotinib). Radiation therapy within 2 weeks of treatment day 1 (except for erlotinib).
- Prior treatment with both pemetrexed and docetaxel chemotherapy.
- Pregnancy or breastfeeding or not receiving adequate contraception (including the patient's spouse).
- Other severe acute or chronic medical or psychiatric conditions or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study.
- Patients who must receive pemetrexed and have the presence of third space fluid which cannot be controlled by drainage.
- Patients who must receive docetaxel and who have peripheral neuropathy > grade 2
- Patients who must receive docetaxel and who have had a hypersensitivity reaction to medications formulated with polysorbate 80
Download the Cleveland Clinic Cancer Clinical Trials App
Stay up to date on Cleveland Clinic’s more than 200 active clinical trials for cancer patients. Our free Cancer Clinical Trials app is available for Apple and Android devices.
With this app, you can:
- Search our real time database for trials by disease, phase, physician or hospital location
- Browse information on each trial’s objective, eligibility criteria, stage(s) and more
- Connect to our Cancer Answer Line for more information about a trial or to enroll patients
The app also includes contacts for patient resources, financial services information, support groups and treatment guides.
Cancer Answers & Appointments
Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.
Monday through Friday from 8 a.m. – 4:30 p.m. (ET).
Resources for medical professionals
- Outpatient appointment referrals: 216.444.7923 or 866.223.8100
- Inpatient hospital transfers: 800.553.5056
- Referring Physician Concierge: 216.444.6196 or 216.312.4910.
Search available cancer clinical trials by disease, hospital, phase or number.
This information is provided by Cleveland Clinic and is not intended to replace
the medical advice of your doctor or health care provider.
Please consult your health care provider for advice about a specific medical condition.
© Copyright 2016 Cleveland Clinic. All rights reserved.